HOLLISTON, Mass.--(BUSINESS WIRE)--Veristat, LLC., a leading, Boston-based clinical research organization today announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem, Inc. (NASDAQ: VSTM). The enhanced design aims to optimize the current trial of defactinib, a novel, small molecule inhibitor of focal adhesion kinase (FAK) in patients with malignant pleural mesothelioma.
Help employers find you! Check out all the jobs and post your resume.
